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Introduction 
Thrombocytopenia is defined as a 
decrease in platelet count to less than 150 
x109/L.1 It can result in increased length of 
hospital stay and risk of death. Drug-induced 
thrombocytopenia (DITP) can result from a 
decrease in platelet production through a 
direct toxic effect on the thrombopoietic 
mechanisms in the bone marrow or an 
increase in platelet destruction through 
immune-mediated mechanisms.2 In DITP, 
the platelet count typically falls from 50 to 
80% of the normal value on exposure to the 
offending drug and returns to normal after 
drug withdrawal.3  
Thrombocytopenia is a rare adverse 
effect of famotidine therapy.4-7 Few cases of 
famotidine-induced thrombocytopenia have 
been reported. Case reports have suggested 
two potential mechanisms of H2 antagonist-
induced thrombocytopenia. The first is bone 
marrow suppression secondary to inhibition 
of DNA synthesis. The second mechanism 
occurs rarely and is the development of 
platelet antibodies during H2-antagonist 
administration.8 The diagnosis of this critical 
condition is based on clinical suspicion and 
is a diagnosis of exclusion. 
We report a case of a male presenting 
with nausea, vomiting, and abdominal pain 
diagnosed with small bowel obstruction.  
 
Case Report 
A 56-year-old Caucasian male weighing 
35 kg (77 pounds) with a history of human 
immunodeficiency virus (HIV), hypo-
thyroidism, chronic obstructive pulmonary 
disease, chronic kidney disease and 
hypertension was hospitalized due to 
vomiting and abdominal pain. His vital signs 
on admission were within normal limits. He 
denied melena, hematochezia, or 
hematemesis. His home medications were 
sodium bicarbonate, furosemide, 
alendronate, L-thyroxine, emtricitabine-
tenofovir, potassium chloride, 
lopinavir/ritonavir, and tiotropium bromide. 
All were taken orally and continued during 
hospitalization. Metronidazole and heparin 
were added. Routine admission labs 
revealed a white blood count of 4900 
cells/mm3 and platelet count of 275 x 109 
platelets/L. Hemoglobin was 13.8 g/dL. An 
abdominal x-ray showed multiple air-fluid 
levels and he was diagnosed with small 
bowel obstruction.  
On day three in the hospital, total 
parenteral nutrition (TPN) containing 
famotidine was initiated. The dose of 
famotidine was 40 mg daily. On day four, a 
complete blood count revealed a platelet 
count of 169 x 109 platelets/L. On day five, 
the platelet count dropped to 157 x 109 
platelets/L. The patient was on heparin and 
heparin-induced thrombocytopenia (HIT) 
was suspected. After stopping all forms of 
heparin on day five, his platelet count 
continued to drop, a trend which continued 
on days six, seven, and eight: 119 × 109 
platelets/L, 100 × 109 platelets/L, 80 × 109 
platelets/L, respectively (Figure 1). 
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Figure 1. Platelet count changes over twelve hospital days. 
 
Work-up for thrombocytopenia included 
a blood smear which showed platelets to be 
of normal size and no schistocytes. PT/INR, 
TSH, vitamin B12, serum and RBC folate 
levels, transaminases, haptoglobin, 
fibrinogen, and partial thromboplastin time 
(PTT) were within normal ranges. Further 
workup revealed a negative ANA and 
minimally elevated d-dimer (3.3; normal, 
0.0-0.5). Hepatitis C was negative and HIV 
viral load was stable with no 
thrombocytopenia since 2009. The patient’s 
heparin-induced antibody result by enzyme-
linked immuno-sorbent assay (ELISA) was 
negative.  
After reviewing his medications, 
famotidine was stopped on the eighth day. A 
significant improvement in the platelet count 
was noticed. Heparin was thought to be safe 
to reintroduce and the platelet count 
continued to improve. The patient had an 
uneventful recovery and was discharged 
four days later with normal platelet counts. 
 
Discussion 
Our patient was diagnosed with 
thrombocytopenia while hospitalized. The 
differential diagnosis included thrombotic 
thrombocytopenic purpura (TTP), 
disseminated intravascular coagulation 
(DIC), liver disease, hepatitis C infection, 
heparin-induced thrombocytopenia (HIT), 
thyroid disease, autoimmune disease, and 
DITP. TTP was ruled out because there was 
no evidence of microangiopathic hemolytic 
anemia, evidenced by the absence of 
schistocytes in the peripheral blood smear 
and normal lactate dehydrogenase and 
bilirubin levels. There was no evidence of 
disseminated intravascular coagulation, as 
fibrinogen and activated PTT were within 
normal limits. Liver function test values 
were normal and hepatitis C antibody was 
negative. TSH was normal. HIT was ruled 
out after negative HIT antibody and platelet 
counts continued dropping after stopping 
heparin. Re-challenge with heparin was 
done after the platelet count returned to 
normal and continued to rise.  
Since other causes of thrombocytopenia 
were ruled out, it was possible that the 
patient had DITP. DITP often is suspected in 
patients with acute thrombocytopenia 
unexplained by other causes, but 
documenting that the drug is the cause of 
thrombocytopenia can be challenging. 
TPN started. 
Heparin and heparin  
flushes stopped. 
Famotidine switched  
to omeprazole. 
Heparin 
resumed.
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Several drugs have been implicated in the 
cause of acute thrombocytopenia, such as 
quinine, quinidine, trimethoprim/ sulfa-
methoxazole and vancomycin.9,10 The 
estimated incidence of DITP is around 1-2 
per 100,000 per year.11,12 There are three 
possible mechanisms by which a drug 
causes a decrease in platelet count: failure of 
production by bone marrow, immune 
destruction, and platelet aggregation in 
circulating blood. Antibodies that bind to 
normal platelets in the presence of a drug 
have been implicated for drugs like 
cinchona, quinine, and sulfa.13,14 The median 
time for daily drug exposure before 
thrombocytopenia is six days (range 1 to 
10),15 but it may appear within 12 hours of 
drug intake in a sensitized individual.16,17 
Typically, the platelet count falls to 80% of 
the normal and thrombocytopenia may be 
associated with neutropenia and anemia. 
Famotidine was the most likely cause of 
our patient’s thrombocytopenia. After the 
patient was switched to omeprazole, his 
platelet count improved within 24 hours, 
reached the normal range on the third day 
off famotidine and remained in the normal 
range thereafter. There is an association 
between the elimination half-life of a drug 
and the time to platelet recovery; recovery 
takes longer with drugs that have longer 
elimination half-lives.1 The average 
elimination half-life of famotidine is three 
hours. With four half-lives (i.e., 12 hours) 
approximately 94% of the drug is eliminated 
from the body. Therefore, it was reasonable 
to expect some improvement in platelet 
count within 12-24 hours after stopping 
famotidine.  
In our case, there was a temporal 
relationship between the initiation of 
famotidine and the onset of thrombo-
cytopenia, and reasonable exclusion of other 
potential causes, making famotidine the 
probable cause. According to the Naranjo 
adverse drug reaction probability scale,18 the 
probability that famotidine caused 
thrombocytopenia in our patient is probable. 
The famotidine product label includes 
thrombocytopenia as a rare hematologic side 
effect. Re-exposure to famotidine was not 
done in our case for patient safety. Also, 
serum was not sent to demonstrate drug-
dependent platelet reactive antibodies in 
vitro. This rare drug reaction due to 
famotidine is more common in critically ill 
neurosurgical and trauma patients.19,20 
Hence, precaution should be taken to put 
these patients on other medications for ulcer 
prophylaxis. 
 
Conclusion 
In cases of severe thrombocytopenia 
unexplained by other causes, a 
pharmacological cause must be suspected, 
particularly famotidine. Other alternate drug 
regimens for prophylaxis of stress ulcer 
should be considered, especially in critically 
ill patients. 
 
References 
1 van den Bemt PM, Meyboom RH, Egberts 
AC. Drug-induced immune thrombo-
cytopenia. Drug Saf 2004; 27(15):1243-
1252. PMID: 15588119. 
2 Liersch T, Beyer JH, Krieger G, 
Vehmeyer K. The growth capacity of 
hematopoietic progenitor cells in severe 
neutropenia induced by famotidine. Ann 
Hematol 1992; 64(5):231-239. PMID: 
1623058. 
3 McGuigan JE. A consideration of the 
adverse effects of cimetidine. Gastro-
enterology 1981; 80(1):181-192. PMID: 
7004992. 
4 Comer JB, Evans JA, Kerns A. Possible 
famotidine-induced thrombocytopenia. 
Kansas Journal of Medicine 2015                     Famotidine-Induced Thrombocytopenia 
 
29 
 
Drug Intell Clin Pharm 1989; 23(6):507-
508. PMID: 2568035 
5 Zimmermann AE, Katona BG, 
Hrehorovich VR. Probable famotidine-
induced thrombocytopenia. DICP 1991; 
25(6):678. PMID: 1877281. 
6 Humphries JE. Thrombocytopenia 
associated with famotidine in a 
hemophiliac. Ann Pharmacother 1992; 
26(2):262. PMID: 1554943. 
7 Oymak O, Akpolat T, Arik N, Yasavul U, 
Turgan C, Caglar S. Reversible 
neutropenia and thrombocytopenia during 
famotidine treatment. Ann Pharmacother 
1994; 28(3):406-407. PMID: 8193440.  
8 Glotzbach RE. Cimetidine-induced 
thrombocytopenia. South Med J 1982; 
75(2):232-234. PMID: 7058369. 
9 Arnold, DM, Nazi I, Warkentin TE, et al. 
Approach to the diagnosis and 
management of drug-induced immune 
thrombocytopenia. Transfus Med Rev 
2013; 27(3):137-145. PMID: 23845922. 
10 Al-Nouri ZL, George JN. Drug induced 
thrombocytopenia: An updated systematic 
review. Drug Saf 2012; 35(8):693-694. 
PMID: 22762135. 
11 Bottiger LE, Westerholm B. Thrombo-
cytopenia. I. Etiology and pathogenesis. 
Acta Med Scand 1972; 191(6):535-540. 
PMID: 5064530. 
12 Kaufman DW, Kelly JP, Johannes CB, et 
al. Acute thrombocytopenic purpura in 
relation to the use of drugs. Blood 1993; 
82(9):2714-2718. PMID: 8219224. 
13 Berndt MC, Chong BH, Boll HA, Zola H, 
Castaldi PA. Molecular characterization of 
quinine/quinidine, drug-dependent anti-
body platelet interaction using monoclonal 
antibodies. Blood 1985; 66(6):1292-1301. 
PMID: 3904869. 
14 Leach MF, Cooper LK, AuBuchon JP. 
Detection of drug-dependent, platelet-
reactive antibodies by solid-phase red cell 
adherence assays. Br J Haematol 1997; 
97(4):755-761. PMID: 9217173. 
15 Rousan TA, Aldoss IT, Cowley BD Jr, et 
al. Recurrent acute thrombocytopenia in 
the hospitalized patient: Sepsis, DIC, HIT, 
or antibiotic-induced thrombocytopenia. 
Am J Hematol 2010; 85(1):71-74. PMID: 
19802882. 
16 Mann HJ, Schneider JR, Miller JB, 
Delaney JP. Cimetidine-associated 
thrombocytopenia. Drug Intell Clin Pharm 
1983; 17(2):126-128. PMID: 6825566. 
17 Bajjoka AE. Ranitidine-induced thrombo-
cytopenia. Arch Intern Med 1991; 151(1): 
203. PMID: 1985602. 
18 Naranjo CA, Busto U, Sellers EM, et al. A 
method for estimating the probability of 
adverse drug reactions. Clin Pharmacol 
Ther 1981; 30:239-245. PMID: 7249508. 
19 Ecker RD, Wijdicks EF, Wix K, 
McClelland R. Does famotidine induce 
thrombocytopenia in neurosurgical 
patients? J Neurosurg Anesthesiol 2004; 
16(4):291-293. PMID: 15557833. 
20 Compoginis JM, Gaspard D, Obaid A. 
Famotidine use and thrombocytopenia in 
the trauma patient. Am Surg 2011; 77(12): 
1580-1583. PMID: 22273212. 
 
Keywords: thrombocytopenia, famotidine, 
drug-induced abnormality 
